Overview

Overview
 
LeadArtis´s current business model includes the definition of an in-house pipeline and partnerships with other companies oriented to the combination of our technology with that of our collaborators.
 
Trimerbody® can be adapted to numerous protein configurations. There are multiple options to establish such relationships. Should you believe that our technology is of interest, we would be pleased to tell you more details and accommodate flexible avenues for collaboration schemes.  
 
 

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...